8-K 1 tm2120203d1_8k.htm FORM 8-K




Washington, D.C. 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 21, 2021





(Exact Name of Registrant as Specified in its Charter)




Delaware   001-38365   47-1178401

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


295 Madison Avenue, Suite 2400, New York, NY

(Address of Principal Executive Offices, and Zip Code)


(917) 289-1117

Registrant’s Telephone Number, Including Area Code 




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


(Title of each class)  




(Name of each exchange

on which registered)

Common stock, $0.0001 par value   EYEN  

The Nasdaq Stock Market

(Nasdaq Capital Market)


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 8.01.Other Events.


Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate update presentation Eyenovia, Inc. intends to use with various investors and analysts.


Item 9.01.Financial Statements and Exhibits.




  Exhibit No. Description
  99.1 Eyenovia, Inc. corporate update presentation dated June 2021








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 21, 2021 /s/ John Gandolfo
  John Gandolfo
  Chief Financial Officer